Phase 1 N=35 Behavioral Pharmacology of THC and D-limonene
D-limonene and THC Pharmacodynamics
Primary: Mean Peak Change From Baseline Anxiety as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 13.8; 18.7; -1.9 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=33 Behavioral Pharmacology of THC and Alpha-pinene
THC · Alpha-pinene
Primary: Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 5.1; 67.2; 66.1 score on a scale
Phase 2 N=25 Effects of Dronabinol (Oral THC) on Cannabis Use
Marijuana Smoking
Primary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed
Phase 1 N=12 Ph1 Marinol Interaction Study - Part 2 - 1
Marijuana Dependence
Primary: Number of Participants That Experience Cardiovascular Effects of Smoked Marijuana or Has Any Other Combination Side Effects. — 6; 6 participants
Phase 1 N=22 Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL
Phase 2 N=34 Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
Pain Threshold · Mood
Primary: Pain Tolerance — 6.1; 2.8; 4.9; 1.5 seconds
Phase 1 N=10 Opioid and Cannabinoid Interactions
Marijuana Usage · Opioid Use
Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale
Phase 4 N=14 Effects of Pregnancy-associated Hormones on THC Metabolism in Women
Pregnancy Related · Cannabis Use
Primary: Dronabinol Exposure — 7.0; 5.6; 5.1; 5.0 nM*h — p=>0.05
Early Phase 1 N=24 Age-Related Effects of THC
Tolerance · Adolescent Behavior · THC
Primary: Change From Baseline in Profile of Mood States (POMS) — 5.75; 12.46; 18.55; 4.08 units on a scale
Phase 2 N=21 Pregnenolone and Marijuana Dependence
Marijuana Dependence
Primary: Subjective Rating of Marijuana Craving on 1-7 Likert Scale — 1.64; 0.80 units on a scale
Phase 1 N=26 Behavioral Pharmacology of Cannabis and Nicotine
Cannabis · Nicotine
Primary: Amount of Nicotine (mL of Smoke/Vapor) Inhaled — 0; 489.0; 1814.0; 1401.0 Volume in mL
Phase 2 N=29 Enhancing Medication-based Analgesia in Humans
Pain · Cannabis · Opioid Use, Unspecified
Primary: Mean Change From Baseline in Seconds to Withdraw Hand From Cold Pressor Laboratory Pain Task — 25.4; 33.9; 31.7; 36.7 seconds — p=0.61
Phase 3 N=8 Vaping THC From Electronic Cigarettes
Marijuana Dependence
Primary: Mean Delivered and Retained Doses — 0.016; 0.018; 0.026 grams (g)
Phase 2 N=17 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
Tourette Syndrome
Primary: Changes in Tic Severity — 7.6 score on a scale
Phase 2 N=199 The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking
Cannabis Intoxication
Primary: Change in Composite Drive Score (CDS) From Pre-smoking Simulation — -.09; .12; .01; -.17 z-score — p=<0.001
Phase 1 N=26 Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation
Cannabis Toxicology
Primary: Delta-9-tetrahydrocannabinol (THC) Cmax in Blood — 1.4; 3.07; 0.5 ng/mL
Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Phase 4 N=13 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain
Chest Pain
Primary: Frequency of Chest Pain Episodes — 1; 3 participants
Phase 2 N=21 Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
Marijuana Abuse
Primary: Marijuana Use — 2.5; 3.9 Reported uses per day
Early Phase 1 N=60 Individual Differences in Drug Response
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Primary: Change From Baseline in Profile of Mood States (POMS) — 2.58; 4.28; 8.25; 0.7 units on a scale
Phase 2 N=131 Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain
Cannabis · Low Back Pain · Neuropathic Pain
Primary: Numerical Pain Intensity — 6.03; 6.11; 6.24; 5.97 score on a scale — p=0.78
Early Phase 1 N=53 Dronabinol Interactions With Cognitive Enhancing Drug in Humans
Cannabis · Marijuana Abuse
Primary: CANTAB:CAmbridge Neuropsychological Test Automated Battery RVIP: Rapid Visual Information Processing — 0.91; 0.9; 0.92; 0.9 units on a scale
Phase 3 N=122 Combined Pharmacotherapy for Cannabis Dependency
Cannabis Dependence · Marijuana Dependence
Primary: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. — 18; 17 participants
N/A N=190 Using Imaging to Assess Effects of THC on Brain Activity
Intoxication Alcohol · Intoxication THC · Intoxication Combined Alcohol THC
Primary: Change in Concentration of Oxygenated Hemoglobin Between Pre-drug and Post-drug Scans of Patients Completing the N-back Task. — 0.00000000042; -0.00000000126…
Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
Phase 2 N=23 Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
Marijuana Smoking
Primary: Subjective Marijuana Effects — 13; 15; 16; 16 units on a scale (0-100mm)
Phase 2 N=5 Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain
Cannabis · HIV Neuropathy · Pain Syndrome
Primary: Phase 1 - Numerical Pain Rating Scale (NPRS) — 2.2; 2.6; 2.8; 1.4 units on a scale
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
Phase 2 N=156 Dronabinol Treatment for Marijuana Addiction
Marijuana Abuse
Primary: Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial — 14; 12 participants
Phase 1 N=24 Opioid and Cannabinoid Pharmacokinetic Interactions
Pain
Primary: Disposition Kinetics of Morphine and Oxycodone Before and After Cannabis Use — 1.64; -1.11; 0.9; 0.99 Geometric Mean Ratio